Patrick John Finn Sells 2,681 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,681 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $111,422.36. Following the sale, the chief operating officer now owns 237,640 shares of the company’s stock, valued at approximately $9,876,318.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total value of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Trading Up 5.3 %

NASDAQ:TWST traded up $2.28 during trading hours on Wednesday, reaching $45.42. 1,019,545 shares of the company were exchanged, compared to its average volume of 942,883. Twist Bioscience Co. has a twelve month low of $15.85 and a twelve month high of $60.90. The firm has a market cap of $2.66 billion, a PE ratio of -11.89 and a beta of 1.78. The stock’s 50-day moving average is $43.61 and its 200-day moving average is $45.43.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets increased its position in shares of Twist Bioscience by 34.8% during the first quarter. BNP Paribas Financial Markets now owns 171,823 shares of the company’s stock valued at $5,895,000 after acquiring an additional 44,349 shares during the last quarter. SageView Advisory Group LLC acquired a new stake in shares of Twist Bioscience in the first quarter valued at $1,144,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Twist Bioscience in the 1st quarter valued at about $300,000. Sei Investments Co. grew its holdings in Twist Bioscience by 32.7% during the 1st quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after acquiring an additional 55,124 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC grew its stake in shares of Twist Bioscience by 38.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after purchasing an additional 37,376 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TWST shares. Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. raised their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Evercore ISI boosted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Leerink Partners raised their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Finally, Barclays decreased their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.